Market Risers: AstraZeneca, BP, Caledonia Mining Corporation

Broker Ratings

The stock price for AstraZeneca with company EPIC: LON:AZN has stepped up 1.22% or 91.57 points throughout the session so far. Market buyers have remained positive while the stock has been in play. The periods high figure was 7646.76 while the low for the session was 7543. The total volume of shares traded by this point was 549,400 with the daily average number around 2,952,061. The 52 week high for the shares is 10120 about 2590 points in difference on the previous days close and a 52 week low being 6736 is a variance of 794 points. AstraZeneca now has a 20 SMA of 7516.08 and now its 50 day moving average now at 7316.47. The current market capitalisation is £99,893.01m at the time of this report. The currency for this stock is GBX. Market cap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Tuesday, April 27, 2021 at 12:20:25 PM GMT with the stock price trading at 7621.57 GBX.

The share price for BP with company EPIC: LON:BP has risen 1.37% or 4.05 points throughout today’s trading session so far. Traders have so far held a positive outlook throughout the session. The periods high figure was 307.45 dipping to 296. The total volume of shares traded by this point was 20,429,440 with the daily average traded share volume around 51,478,434. The 52 week high for the shares is 508.7 around 212.15 points difference from the previous days close and the 52 week low at 188.52 which is a difference of 108.03 points. BP now has a 20 simple moving average of 302.91 and now its 50 day SMA of 304.71. The market capitalisation is now £61,069.15m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for BP being recorded at Tuesday, April 27, 2021 at 12:20:36 PM GMT with the stock price trading at 300.6 GBX.

The trading price for Caledonia Mining Corporation found using EPIC: LON:CMCL has moved up 4.55% or 50 points throughout today’s trading session so far. Market buyers are a positive bunch while the stock has been in play. The periods high has reached 1150 meanwhile the session low reached 1050. The volume total for shares traded up to this point was 566 with the average number of shares traded daily being 5,327. The 52 week high price for the shares is 1900 amounting to 800 points difference from the previous days close and the 52 week low at 950 a difference of some 150 points. Caledonia Mining Corporation now has a 20 SMA at 1134.19 and also a 50 day simple moving average now at 1141.77. Market capitalisation for the company is £170.39m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Caledonia Mining Corporation being recorded at Tuesday, April 27, 2021 at 9:59:02 AM GMT with the stock price trading at 1150 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

AstraZeneca H1 2026 revenue rises 9% as growth momentum continues

AstraZeneca reported first-half 2026 revenue of $30.7 billion, up 6% at constant exchange rates, with core operating profit and core EPS both rising 11%. Growth in oncology and rare disease offset Farxiga and China headwinds. The company raised its interim dividend, secured 30 approvals, and reaffirmed full-year guidance and its $80 billion 2030 revenue goal.

Astrazeneca reports positive survival data for Sone-Ve in gastric cancer trial

Astrazeneca Plc has reported statistically significant overall survival results for Sone-Ve in the CLARITY-Gastric01 Phase III trial.

Astrazeneca secures EU approval for Etcamah in ER-positive breast cancer

Astrazeneca Plc has secured European Union approval for Etcamah in combination therapy for ER-positive, HER2-negative advanced breast cancer.

BP expects stronger Q2 2026 margins as net debt falls

Bp Plc has provided a second quarter 2026 trading statement, outlining expected production, refining and net debt movements.

Astrazeneca secures global rights to Zegfrovy in EGFR-mutated lung cancer

Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio.

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy...

Search